Merck Nears Cidara Acquisition for Flu Treatments

Merck, a pharmaceutical giant, is reportedly close to acquiring Cidara Therapeutics, a flu treatment specialist, for a premium price. This move aligns with Mercks strategy to diversify revenue streams, especially as its blockbuster cancer drug, Keytruda, nears patent expiration. The acquisition follows Mercks recent purchase of Verona Pharma and is part of a larger trend of increased deal-making in the pharmaceutical sector.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.